Avantor® Reports Fourth Quarter and Full Year 2024 Results

Core Insights - Avantor, Inc. reported a return to growth in Q4 2024, with sequential and year-over-year increases in adjusted EBITDA margin, adjusted EPS, and free cash flow conversion [2][3] - The company experienced a net sales decrease of 2% in Q4 2024 compared to Q4 2023, but achieved 1% organic growth [4][9] - For the full year 2024, net sales were $6,783.6 million, a decrease of 3$500.4 million from $98.5 million in Q4 2023, with an adjusted net income of$183.9 million compared to $166.7 million in the prior period [5][9] - The adjusted EBITDA for Q4 2024 was$307.7 million, with an adjusted EBITDA margin of 18.2% [5][9] - For the full year 2024, net income increased to $711.5 million from$321.1 million in 2023, with an adjusted EBITDA of $1,198.8 million and an adjusted EBITDA margin of 17.7$173.3 million, while free cash flow was $222.1 million [6][9] - For the full year 2024, operating cash flow was$840.8 million, and free cash flow was $768.3 million [10][9] - The adjusted net leverage ratio was 3.2x as of December 31, 2024 [10] Segment Performance - The bioprocessing platform grew in high-single digits, indicating strong performance in that segment [2] - The company’s new operating model and cost transformation program are ahead of schedule, contributing to improved efficiency [3]